Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke

Critical Care

Cheng-Hsien Lu¹  Lian-Hui Lee⁶  Hsueh-Wen Chang¹  Wei-Che Lin³  Yu-Jun Lin⁴  Tzu-Ming Yang⁴  Hung-Chen Wang⁴  Yi-Fang Chiang²  Kuei-Yueh Cheng⁷  Shang-Der Chen⁶  Chi-Ren Huang⁶  Chung-Ren Jan⁵  Wen-Neng Chang⁶  Tsu-Kung Lin⁶  Nai-Wen Tsai⁶ 

[1] Department of Biological Science, National Sun Yat-Sen University, 70 Lien-Hai Road, Kaohsiung, Taiwan;Departments of Research, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung, Taiwan;Departments of Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung, Taiwan;Departments of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung, Taiwan;Department of Medical Education and Research, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st RD, Kaohsiung, 81346, Taiwan;Departments of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung, Taiwan;Departments of Nursing, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung, Taiwan

关键词: platelet activation;    outcome;    ischemic stroke;    flow cytometry;   

Others  :  1094375
DOI  :  10.1186/cc10303

 received in 2011-03-31, accepted in 2011-07-08,  发布年份 2011

【 摘 要 】

Introduction

Statins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterol-lowering. This study aimed to evaluate the effect of pre-existing statin use on platelet activation markers and clinical outcome in acute ischemic stroke patients.

Methods

This prospective study evaluated 172 patients with acute ischemic stroke divided in two groups: patients with pre-existing statin (n = 43) and without pre-existing statin (66 cases with statins initiated post-stroke and 63 without statin treatment). Platelet activation markers (CD62P and CD63) were measured by flow cytometry at different time points after stroke and analyzed with clinical outcome.

Results

The CD62P and CD63 expressions on platelets were significantly lower in the patients with pre-existing statin use compared to the patients without pre-existing statin use on Day 1 post-stroke (p < 0.05). The CD62P expression was significantly lower in the patients with pre-existing statin use on 90 days after the acute stroke (p < 0.05). Patients with pre-existing statin use had lower incidences of early neurologic deterioration (END) than those without treatment (p < 0.05). Among several baseline clinical variables, admission NIHSS score, history of coronary artery disease, and pre-existing statin use were independent predictions of good clinical outcome at three months.

Conclusions

Pre-existing statin use is associated with decreased platelet activity as well as improved clinical outcome and reduced END in patients with acute ischemic stroke.

【 授权许可】

   
2011 Tsai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Suwanwela N, Koroshetz WJ: Acute ischemic stroke: overview of recent therapeutic developments. Annu Rev Med 2007, 58:89-106.
• [2]Ruggeri ZM: Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
• [3]Huang J, Upadhyay UM, Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006, 66:232-245.
• [4]Tsai NW, Chang WN, Shaw CF, Jan CR, Huang CR, Chen SD, Chuang YC, Lee LH, Lu CH: The value of leukocyte adhesion molecules in patients after ischemic stroke. J Neurol 2009, 256:1296-1302.
• [5]Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F, Mayer H, Grau AJ: Course of platelet activation markers after ischemic stroke. Stroke 2002, 33:2570-2574.
• [6]Cha JK, Jeong MH, Jang JY, Bae HR, Lim YJ, Kim JS, Kim SH, Kim JW: Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. Cerebrovasc Dis 2003, 16:376-382.
• [7]Tsai NW, Chang WN, Shaw CF, Jan CR, Chang HW, Huang CR, Chen SD, Chuang YC, Lee LH, Lu CH: Serial change in platelet activation markers with aspirin and clopidogrel after acute ischemic stroke. Clin Neuropharmacol 2010, 33:40-45.
• [8]Hankey GJ: Secondary prevention of recurrent stroke. Stroke 2005, 36:218-221.
• [9]van der Worp HB, van Gijn J: Clinical practice. Acute ischemic stroke. N Engl J Med 2007, 357:572-579.
• [10]Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:1583-1633.
• [11]Alberts AW: Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988, 62:10J-15J.
• [12]Kwak BR, Mach F: Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001, 21:1256-1258.
• [13]Veillard NR, Mach F: Statins: the new aspirin? Cell Mol Life Sci 2002, 59:1771-1786.
• [14]Tonkin A, John R: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349-1357.
• [15]Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M: HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005, 36:1298-1300.
• [16]Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, Hennerici M, Simunovic L, Zivin JA, Welch KM: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007, 38:3198-3204.
• [17]Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ: Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005, 96:611-616.
• [18]Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia M, Molina-Porcel L, Díaz-Manera J, Martí-Vilalta J-L: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004, 35:1117-1121.
• [19]Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W: Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004, 221:5-10.
• [20]Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D: Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 2009, 40:2581-2584.
• [21]Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:577-617.
• [22]Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
• [23]Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Dávalos A, Castillo J: Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007, 69:904-910.
• [24]Lovblad KO, Baird AE: Computed tomography in acute ischemic stroke. Neuroradiology 2010, 52:175-187.
• [25]Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
• [26]Schafer A, Fraccarollo D, Eigenthaler M, Tas P, Firnschild A, Frantz S, Ertl G, Bauersachs J: Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 2005, 25:1071-1077.
• [27]Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F: Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002, 32:901-908.
• [28]Lefer DJ: Statins as potent antiinflammatory drugs. Circulation 2002, 106:2041-2042.
• [29]Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M: Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002, 942:23-30.
• [30]Htun P, Fateh-Moghadam S, Tomandl B, Handschu R, Klinger K, Stellos K, Garlichs C, Daniel W, Gawaz M: Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke 2006, 37:2283-2287.
• [31]Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002, 106:399-402.
• [32]Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995, 75:455-459.
• [33]Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
• [34]Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M: Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003, 34:551-557.
• [35]Li JJ, Li YS, Chen J, Yang JQ: Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses 2006, 66:1199-1204.
• [36]Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC: Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005, 20:120-128.
• [37]Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY: Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002, 40:61-66.